References
- CDC. Complications of Mumps. [accessed 2019 Mar 22]. https://www.cdc.gov/Mumps/about/complications.html.
- WHO. Mumps reported cases. Last update: 21-Sep-2018 (data received as of 18-Sep-18). [accessed 2019 Feb 24]. http://apps.who.int/immunization_monitoring/globalsummary/timeseries/tsincidenceMumps.html.
- CDC. Manual for the surveillance of vaccine-preventable diseases. Chapter 9: Mumps. [accessed 2019 Mar 24]. https://www.cdc.gov/vaccines/pubs/surv-manual/chpt09-Mumps.html.
- CDC. Measles, Mumps, and Rubella (MMR) vaccination: what everyone should know. [accessed 2019 Mar 22]. https://www.cdc.gov/vaccines/vpd/mmr/public/index.html.
- CDC. Epidemiology and prevention vaccine-preventable diseases. Mumps. [accessed 2019 Mar 20]. https://www.cdc.gov/vaccines/pubs/pinkbook/Mumps.html.
- CDC. Measles, Mumps, and Rubella (MMR) vaccine safety. [accessed 2018 Sep 15]. https://www.cdc.gov/vaccinesafety/vaccines/mmr-vaccine.html.
- Zhou F, Reef S, Massoudi M, Papania MJ, Yusuf HR, Bardenheier B, Zimmerman L, McCauley MM. An economic analysis of the current universal 2-dose measles-Mumps-Rubella vaccination program in the United States. J Infect Dis. 2004;189(Suppl 1):S131–45. doi:10.1086/378987.
- Marin M, Marlow M, Moore KL, Patel M. Recommendation of the advisory committee on immunization practices for use of a third dose of mumps virus-containing vaccine in persons at increased risk for mumps during an outbreak. MMWR Morb Mortal Wkly Rep. 2018;67(1):33–38. doi:10.15585/mmwr.mm6701a7.
- Italian Ministry of Health. Decree-Law 07 June 2017, n. 73. Urgent provisions on vaccination prevention. G.U. General Serie, n. 130 of 07 June 2017 [accessed 2019 Dec 30]. http://www.trovanorme.salute.gov.it/norme/dettaglioAtto?id=59548.
- D’Ancona F, D’Amario C, Maraglino F, Rezza G, Ricciardi W, Iannazzo S. Introduction of new and reinforcement of existing compulsory vaccinations in Italy: first evaluation of the impact on vaccination coverage in 2017. Euro Surveill. 2018;23(22). doi:10.2807/1560-7917.ES.2018.23.22.1800238.
- WHO Europe. Eliminating measles and Rubella and preventing congenital Rubella infection. [accessed 2019 Dec 30]. http://www.euro.who.int/__data/assets/pdf_file/0008/79028/E87772.pdf.
- Gabutti G, Guido M, Rota MC, De Donno A, Ciofi Degli Atti ML, Crovari P. Seroepidemiology group. Epidemiol Mumps in Italy Vaccine. 2008;26:2906–11.
- CDC. Immunization of health-care personnel. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity and mortality weekly report. Recommendations and Reports/Vol. 60/No. 7. 2011 Nov 25. https://www.cdc.gov/mmwr/pdf/rr/rr6007.pdf.
- Date AA, Kyaw MH, Rue AM, Klahn J, Obrecht L, Krohn T, Rowland J, Rubin S, Safranek T, Bellini W, et al. Long-term persistence of mumps antibody after receipt of 2 measles-mumps-rubella (MMR) vaccinations and antibody response after a third MMR vaccination among a university population. J Infect Dis. 2008;197:1662–68. doi:10.1086/590464.
- Cortese MM, Jordan HT, Curns AT, Quinlan P, Ens K, Denning P, Dayan G. Mumps vaccine performance among university students during a mumps outbreak. Clin Infect Dis. 2008;46:1172–80. doi:10.1086/588450.
- Harling R, White JM, Ramsay ME, Macsween KF, Bosch CVD. van den Bosch C. The effectiveness of the mumps component of the MMR vaccine: a case control study. Vaccine. 2005;23:4070–74. doi:10.1016/j.vaccine.2004.10.020.
- Smetana J, Chlibek R, Hanovcova I, Sosovickova R, Smetanova L, Polcarova P, Gal P, Dite P. Serological survey of Mumps antibodies in adults in the Czech Republic and the need for changes to the vaccination strategy. Hum Vaccin Immunother. 2018;14(4):887–93. doi:10.1080/21645515.2017.1412021.
- Tafuri S, Gallone MS, Larocca AM, Germinario C. How will the MMR universal mass vaccination change the epidemiologic pattern of Mumps? A 2012 Italian serosurvey. Am J Infect Control. 2016;44(11):1420–21. doi:10.1016/j.ajic.2016.03.012.
- Tafuri S, Martinelli D, Caputi G, Arbore A, Lopalco PL, Germinario C, Prato R. An audit of vaccination coverage among vaccination service workers in Puglia, Italy. Am J Infect Control. 2009;37(5):414–16. doi:10.1016/j.ajic.2008.10.030.
- Bianchi FP, Gallone MS, Gallone MF, Larocca AMV, Vimercati L, Quarto M, Tafuri S. HBV seroprevalence after 25 years of universal mass vaccination and management of non-responders to the anti-Hepatitis B vaccine: an Italian study among medical students. J Viral Hepat. 2019 Jan;26(1):136–44.
- Tafuri S, Gallone MS, Gallone MF, Pappagallo MT, Larocca AMV, Germinario C. Monitoring the process of Measles elimination by serosurveillance data: the Apulian 2012 study. Vaccine. 2016;34(18):2092–95. doi:10.1016/j.vaccine.2016.03.011.
- DiaSorin. The diagnostic specialist. LIAISON® Mumps IgG. The fully automated solution for antibody detection. [accessed 2019 Dec 30]. https://www.diasorin.com/sites/default/files/allegati_prodotti/scheda_mumps_igg.pdf.
- Cabrillo College. Clinical compliance basics. Health screening. measles, Mumps, Rubella (MMR). [accessed 2018 Nov 04]. https://www.cabrillo.edu/services/health/clinical-compliance/clinical-mumps.html.
- Flanagan KL, Fink AL, Plebanski M, Klein SL. Sex and gender differences in the outcomes of vaccination over the life course. Annu Rev Cell Dev Biol. 2017;33:577–99. doi:10.1146/annurev-cellbio-100616-060718.
- Ruggieri A, Anticoli S, D’Ambrosio A, Giordani L, Viora M. The influence of sex and gender on immunity, infection and vaccination. Ann Ist Super Sanita. 2016;52(2):198–204. doi:10.4415/ANN_16_02_11.
- Klein SL, Marriott I, Fish EN. Sex-based differences in immune function and responses to vaccination. Trans R Soc Trop Med Hyg. 2015;109(1):9–15. doi:10.1093/trstmh/tru167.
- Date AA, Kyaw MH, Rue AM, Klahn J, Obrecht L, Krohn T, Rowland J, Rubin S, Safranek TJ, Bellini WJ, et al. Long-term persistence of Mumps antibody after receipt of 2 measles-Mumps-Rubella (MMR) vaccinations and antibody response after a third MMR vaccination among a university population. J Infect Dis. 2008;197(12):1662–68. doi:10.1086/590464.
- Cardemil CV, Dahl RM, James L, Wannemuehler K, Gary HE, Shah M, Marin M, Riley J, Feikin DR, Patel M, et al. Effectiveness of a third dose of MMR vaccine for Mumps outbreak control. N Engl J Med. 2017;377:947–56. doi:10.1056/NEJMoa1703309.
- Ogbuanu IU, Kutty PK, Hudson JM, Blog D, Abedi GR, Goodell S, Lawler J, McLean HQ, Pollock L, Rausch-Phung E, et al. Impact of a third dose of measles-Mumps-rubella vaccine on a Mumps outbreak. Pediatrics. 2012;130:e1567–74. doi:10.1542/peds.2012-0177.
- Marlow M. Grading of recommendations assessment, development and evaluation (GRADE): third dose of MMR vaccine. Presentation at the Advisory Committee on Immunization Practices meeting; 2017 Oct 25–26; Atlanta (GA). https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2017-10/Mumps-03-marlow-508.pdf.
- Albertson JP, Clegg WJ, Reid HD, Arbise BS, Pryde J, Vaid A, Thompson-Brown R, Echols F. Mumps outbreak at a university and recommendation for a third dose of measles-Mumps-rubella vaccine—Illinois, 2015–2016. MMWR Morb Mortal Wkly Rep. 2016;65:731–34. doi:10.15585/mmwr.mm6529a2.
- Bonebrake AL, Silkaitis C, Monga G, Galat A, Anderson J, Trad TJ, Hedley K, Burgess N, Zembower TR. Effects of Mumps outbreak in hospital, Chicago, Illinois, USA, 2006. Emerg Infect Dis. 2010;16(3):426–32. doi:10.3201/eid1603.090198.